Mallinckrodt deal signals turnaround for Silence at potential $693M per target July 22, 2019 By Nuala Moran No Comments LONDON – Silence Therapeutics plc has finally secured a deal to transform its fortunes, signing up Mallinckrodt plc in a potential $693 million-per-asset collaboration to develop siRNA therapeutics that block the complement inflammatory cascade.Read More
FUD peptide targeting fibronectin patented by Wisconsin Alumni Research Foundation June 19, 2019 No Comments
Inhibiting CCL24 with CM-101 reduces fibrosis and inflammation in systemic sclerosis June 18, 2019 No Comments
RSS